Mark P. de Caestecker

Personal Information
Title Professor
Expertise None Selected
Institution Vanderbilt University
Newsletter? Not signed up.
Data Summary
TypeCount
Grants/SubContracts 1
Progress Reports 1
Publications 2
Protocols 0
Committees 0

Use of a novel PTBA analogue to ameliorate CKD progression after AKI in experimental diabetic nephropathy
The goal of these studies is to evaluate the effects of short-term treatment with a novel class of HDAC inhibitors on long-term chronic kidney disease (CKD) progression after acute kidney injury (AKI) in experimental diabetic nephropathy (DN). Studies are part of an on-going collaborative research program with Neil Hukriede from Pittsburgh, to develop novel therapeutics that reduce post-AKI fibrosis and are effective when administered late after the initiating injury. The specific focus of this pilot project is to determine whether our lead agent, UPHD186, is effective in preventing post AKI fibrosis and progressive CKD in the context of both mild and severe experimental DN, in order to define potential therapeutic applications of this agent.

Progress Reports

Annual Reports
No uploaded documents found.


 PublicationAltmetricsSubmitted ByPubMed IDStatus

Year: 2017; Items: 1
 
Drug Discovery to Halt the Progression of Acute Kidney Injury to Chronic Kidney Disease: A Case for Phenotypic Drug Discovery in Acute Kidney Injury.
Hukriede N, Vogt A, de Caestecker M
Nephron, 2017
de Caestecker, Mark P.
28614822
Published

Year: 2016; Items: 1
 
Delayed treatment with PTBA analogs reduces postinjury renal fibrosis after kidney injury.
Skrypnyk NI, Sanker S, Skvarca LB, Novitskaya T, Woods C, Chiba T, Patel K, Goldberg ND, McDermott L, Vinson PN, Calcutt MW, Huryn DM, Vernetti LA, Vogt A, Hukriede NA, de Caestecker MP
American journal of physiology. Renal physiology, 2016 (310), F705 - F716
de Caestecker, Mark P.
26661656
Published
No uploaded documents found.
No protocols found.
No committees found.
ExperimentSpeciesStatusMeasurementsOptions
No records to display.